LLY Jun 2024 270.000 call
| Previous close | 199.15 |
| Open | 199.33 |
| Bid | 201.55 |
| Ask | 205.90 |
| Strike | 270.00 |
| Expiry date | 2024-06-21 |
| Day's range | 199.15 - 199.33 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
PR NewswireMore than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically significant and clinically meaningful improvements across multiple clinical and endoscopic endpoints at one year with mirikizumab compared to placebo. Data from this study – the first Phase 3 treat-through data reported for an IL23p19 antibody – will be presented at Digestive Disease Week® (DDW), held
ReutersEli Lilly's diabetes drug tirzepatide gets approval in China
SHANGHAI (Reuters) -Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market. Novo Nordisk's popular diabetes drug Ozempic won approval from China in 2021 and the company saw sales of the weekly injection in the greater China region that includes Hong Kong and Taiwan double to 4.8 billion Danish Krone ($698 million) last year. Eli Lilly did not say when sales would begin in China or how many doses would be supplied.
Investor's Business DailyMagnificent Seven? Just Two Members Clear This Bar
Ultimately, earnings drive share prices. Only two Magnificent Seven stocks, and a third megacap, meet this triple-25% growth standard.
